New Biotechnology Coalition Seeks to Boost Antibiotics Development

Christopher Cheney

September 16, 2019

A new coalition of biotechnology stakeholders has formed to promote development of new antibiotics to fight antimicrobial resistance.

The Centers for Disease Control and Prevention estimates more than 2 million Americans experience a drug-resistant infection annually, with at least 23,000 deaths. A new estimate from the Washington University School of Medicine in St. Louis puts the annual death toll as high as 162,000.

Working to Fight AMR launched in August to close the gap in the pharmacological arms race between deadly microbes and antibiotic treatments, the new coalition’s director told HealthLeaders last week.

Name
First Last
Email
Zipcode
Organization
Title
Email
This field is for validation purposes and should be left unchanged.

HealthLeaders

New Biotechnology Coalition Seeks to Boost Antibiotics Development

Christopher Cheney

September 16, 2019

More

Wall Street Journal

The World Needs New Antibiotics. The Problem Is, No One Can Make Them Profitably.

Pharmaceutical Technology

Fighting AMR with a value and subscription model

Fierce Biotech

Scientists use AI to find new antibiotics, but can they climb out of the ‘valley of death’ to the clinic?

PHARMAVOICE

‘The Last of Us’ might be fiction, but fungi are a looming threat

Sign up for the latest on fighting AMR